Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06150469

Efficacy of Inhaled Aromatherapy on Nausea and Vomiting in Hematological Malignancies

This project will optimise the management of chemotherapy-induced nausea and vomiting, with improvements in nausea and vomiting scores, quality of life and appetite expected in participants benefiting from the intervention. In all cases, the use of complementary methods is recommended and improves the management of people with cancer because they offer a person-centred approach.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Hematological Malignancies Hematologic Diseases Hematologic Neoplasms Hemic and Lymphatic Diseases Neoplasms Neoplasms by Site

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CH BRIVE, Brivé, France

Loading trial locations.

About this study

The aim is to evaluate the efficacy of inhalation of a mixture of ginger and lemon Essential Oils (EO) versus placebo in addition to conventional antiemetic treatments on the intensity of chemo-induced nausea during the acute phase D1 (H24) of its onset in patients with C1 haematological malignancies.

This multicentre study will be carried out in 5 establishments (haematology and oncology care sectors), which represents a very high potential for inclusion.

In addition, the investigator expect a very high acceptance rate for this study. In fact, in the context of CINV, this care strategy may meet a patient's expectation of symptoms (nausea, vomiting) that they find difficult to manage. Finally, it is known that patients in these care sectors are very keen on supportive care to improve their quality of life, so this is a potentially very interesting opportunity without any particular risk that is offered to participants in this study.

A nurse and a doctor with a postgraduate diploma in aromatherapy are coordinating the team, with the support of a nurse trained in evidence-based practice research methodology. Institutional procedures drawn up by the team at Limoges University Hospital describe the general procedure for using aromatherapy in a scientific and safe way, the protocols that can be used to describe the operating methods, the traceability of the manufacture of the mixtures and their administration, and the evaluation of their effectiveness. Supporting documents, an information note and a monitoring sheet have been created and are being used.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged over 18 years,
  • Chemo-naive patients at inclusion,
  • Patients with haematological malignancies treated treated with chemotherapy,
  • Patients physically and mentally able to use the aromastick,
  • Patients who speak, read and write French,
  • Patients who have given signed consent,
  • Patients with social security cover.

Exclusion criteria

  • Asthmatic patients.
  • Patients with anosmia.
  • Patients allergic to EO, lemon or ginger.
  • Patients who have already received aromatherapy to treat chemotherapy-induced nausea and vomiting,
  • Patients practising herbal medicine or acupuncture,
  • Pregnant and breast-feeding women,
  • Patients under guardianship, tutorship or curatorship,
  • Patients taking part in interventional studies involving antiemetic drugs or nutritional products,
  • Patients who have already had cancer.

Treatment and study plan

"Blend of ginger and lemon essential oils", "Neutral oil"

Combination Product

Patients will be given aromasticks to inhale the blend of essential oils.

Primary outcomes

  1. Efficacy of inhaled aromatherapy on acute nausea

    Time frame: 1 month, 2 months and 3 months

    To assess difference of nausea intensity score measured by MAT Tool between groups oils (EO) of ginger and lemon versus placebo in addition to addition to conventional antiemetic treatments on intensity of chemo-induced nausea during the acute phase D1 (H24) of onset in patients with haematological malignancies C1 haematological malignancies.

    MAT is used to self-assess the prevention and control of chemotherapy-induced nausea and vomiting. It comprises 2 evaluation parts: the first is a Likert scale assessing the intensity of chemotherapy-induced nausea (0-10), and the second is a record of the frequency of vomiting in the acute (H24) and delayed (H96) phases of chemo-induced nausea and vomiting onset.

Secondary outcomes

  1. Efficacy of inhaled aromatherapy on vomiting frequency

    Time frame: 1 day, 1 month

    To evaluate difference of vomiting fréquency measure by MAT Tool between groups.

    MAT is used to self-assess the prevention and control of chemotherapy-induced nausea and vomiting. It comprises 2 evaluation parts: the first is a Likert scale assessing the intensity of chemotherapy-induced nausea (0-10), and the second is a record of the frequency of vomiting in the acute (H24) and delayed (H96) phases of chemo-induced nausea and vomiting onset.

  2. Efficacy of inhaled aromatherapy on acute nausea between 4 days and 1 month

    Time frame: 4 days, 1 month

    To assess difference of nausea intensity score measured by MAT Tool between groups.

    MAT is used to self-assess the prevention and control of chemotherapy-induced nausea and vomiting. It comprises 2 evaluation parts: the first is a Likert scale assessing the intensity of chemotherapy-induced nausea (0-10), and the second is a record of the frequency of vomiting in the acute (H24) and delayed (H96) phases of chemo-induced nausea and vomiting onset.

  3. Efficacy of inhaled aromatherapy on vomiting frequency between 4 days and 1 month

    Time frame: 4 days, 1 month

    To evaluate difference of vomiting fréquency measure by MAT Tool between groups.

    MAT is used to self-assess the prevention and control of chemotherapy-induced nausea and vomiting. It comprises 2 evaluation parts: the first is a Likert scale assessing the intensity of chemotherapy-induced nausea (0-10), and the second is a record of the frequency of vomiting in the acute (H24) and delayed (H96) phases of chemo-induced nausea and vomiting onset.

  4. Efficacy of inhaled aromatherapy

    Time frame: 1 month, 2 months and 3 months

    To compare the efficacy of inhaled aromatherapy on the evolution of nausea intensity in the acute phase acute phase (D1) and then the delayed phase (D4) chemotherapy cycles (C1, C2 and C3).

    MAT is used to self-assess the prevention and control of chemotherapy-induced nausea and vomiting. It comprises 2 evaluation parts: the first is a Likert scale assessing the intensity of chemotherapy-induced nausea (0-10), and the second is a record of the frequency of vomiting in the acute (H24) and delayed (H96) phases of chemo-induced nausea and vomiting onset.

  5. Anticipatory nausea

    Time frame: 1 month, 2 months and 3 months

    Compare the intensity of chemo-induced nausea. Compared the mean difference of anticipatory nausea intensity score measured by a Likert scale (ranging from 0-10 with zéro none and 10 as much as possible) between groups before the start of each cycle of chemotherapy (C1, C2, C3) between groups.

  6. Compare the proportion of chemically-induced emesis

    Time frame: 1 month, 2 months and 3 months

    Compare the proportion of chemically-induced emesis before the start of each cycle of chemotherapy (C1, C2, C3) between groups.

  7. Independent determinants of the presence of nausea then vomiting

    Time frame: 1 month, 2 months and 3 months

    To identify, in patients who received aromatherapy, the association between independent determinants of the presence of nausea then vomiting at the acute phase (D1) and at the delayed phase (D4) of the first cycle of chemotherapy (C1) (sex, age, anticipation of CINV, nausea terrain, history of nausea/vomiting, history of chemotherapy, motion sickness, tolerance of EO odour).

  8. Compare and describe the use of antiemetics use of antiemetics

    Time frame: 1 month, 2 months and 3 months

    Compare and describe the use of antiemetics use of antiemetics and write down the use of EO inhalations EO inhalations "if needed" during the acute (D1), delayed (D4) and anticipated phase of CINV (H0) during the 3 cycles of chemotherapy (C1, C2 and C3).

  9. Impact of inhaled aromatherapy on quality of life

    Time frame: 1 month, 2 months and 3 months

    Compare quality of life between the two groups at each each cycle of chemotherapy (C1,C2 and C3). Difference of quality of life score (EORTC QLQC30) between groups at each cycle.

    EORTC QLQC 30 is European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire.

    This self-questionnaire, validated in French, assesses quality of life specific to cancer. It is intended for all cancer patients, regardless of location.

    EORTC QLQC 30 contains 30 items and assesses 15 dimensions of quality of life :

    • 5 functional scales: physical, cognitive, social, emotional or psychological and limitations in daily activities;
    • 1 global health/quality of life scale;
    • 9 symptom scales: tiredness, nausea and vomiting, pain, dyspnea, insomnia, loss of appetite, constipation and diarrhea, financial problems related with the disease.

  10. Efficacy of inhaled aromatherapy on dietary intake

    Time frame: 1 month, 2 months and 3 months

    To compare the effect of inhalation of ginger + lemon EO versus placebo in addition to conventional antiemetic treatments on diet during C1, C2, C3. Difference of dietary intake measured by SEFI scale between groups.

    SEFI (Score d'Evaluation Facile des Ingesta - Ingesta Easy Evaluation Score) / LA description : SEFI is a visual assessment, by the patient himself or with the help of a caregiver, of his food intake, using an analog scale (0 to 10), or a choice of portions consumed.

Sponsors and collaborators

Lead sponsor

University Hospital, Limoges

Other

Registry information

Official study title

Efficacy of Ginger and Lemon Essential Oil Inhalation on Chemotherapy-induced Nausea and Vomiting in Patients with Haematological Malignancies: a Multicenter, Double-blind, Randomised Controlled Trial

Acronym: AROM-HEMATO

Important dates

Study start
2024
Primary completion
2025
Study completion
2026
First posted
Nov 29, 2023
Registry last updated
Dec 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.